Insulet Co. (NASDAQ:PODD) Shares Sold by Algert Global LLC

Algert Global LLC lessened its position in Insulet Co. (NASDAQ:PODD) by 14.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,482 shares of the medical instruments supplier’s stock after selling 1,649 shares during the period. Algert Global LLC’s holdings in Insulet were worth $2,475,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PODD. Horizon Investments LLC increased its stake in shares of Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after acquiring an additional 42 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Insulet by 1.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after purchasing an additional 43 shares during the period. Graypoint LLC boosted its holdings in shares of Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 47 shares during the last quarter. Wilmington Savings Fund Society FSB grew its stake in shares of Insulet by 9.6% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock valued at $140,000 after buying an additional 47 shares during the period. Finally, Envestnet Portfolio Solutions Inc. increased its holdings in shares of Insulet by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier’s stock worth $552,000 after buying an additional 48 shares during the last quarter.

Insulet Price Performance

Shares of PODD stock opened at $257.00 on Friday. The firm has a fifty day moving average of $256.64 and a two-hundred day moving average of $262.99. The firm has a market cap of $18.08 billion, a P/E ratio of 44.39, a P/E/G ratio of 3.62 and a beta of 1.26. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. During the same period last year, the company earned $0.73 earnings per share. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. As a group, research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on PODD. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a research report on Monday, April 28th. Stifel Nicolaus raised their price target on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a report on Friday, February 21st. Piper Sandler boosted their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group raised their target price on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $299.81.

Insider Buying and Selling

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company’s stock, valued at $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.47% of the stock is currently owned by company insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.